NKTR: Nektar Therapeutics Growth-Adjusted Market Cap to Net Income
Nektar Therapeutics (NKTR) relies on unique drug modification methods to generate royalties from pharmaceutical behemoths. The P/E ratio relative to business expansion rates reflects current price action, where 0.00 determines this parameter level. However, weak pricing power and a dependence on grants coupled with a high cash burn rate make the asset risky due to the uncertainty of future clinical trials.
Metric breakdowns and analytics for Nektar (NKTR)
- share price and consensus valuation forecast:
- market capitalization information:
- company book value details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Nektar Therapeutics|NKTR - Long-Term Debt to Equity|Short-Term Debt to Capital Ratio Nektar Therapeutics Inc.|NKTR - Company Aggregate Debts|Debts to Book Value Nektar Therapeutics|NKTR - Company Long-Term Debt|Company Short-Term Indebtedness Nektar Therapeutics|Immediate Liquidity nektar.com
- business earnings and investment ratios data:
NKTR - Company Net Income|Projected Future Earnings Nektar Therapeutics|NKTR - Price to Earnings Ratio|Market Cap to Future Earnings Ratio Nektar Therapeutics|NKTR - PEG Multiple|EV/EBITDA Multiple Nektar Therapeutics|NKTR - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Nektar Therapeutics|NKTR - Net earnings per share for the last 12 months|Year-over-year earnings per one share growth for the last 12 months nektar.com|NKTR - Net earnings per share growth this year|Projected earnings per share increase next year Nektar Therapeutics
- total revenue and sales volume data:
General company analysis:NKTR - Nektar Corp
Analyzing the PEG ratio history for Nektar Therapeutics (NKTR), we assess the balance between market valuation and earnings growth, where a ratio below one signals that the asset is undervalued. This metric is critical for Nektar Therapeutics (NKTR), as it weighs current quotes against the development potential of immunotherapy amid investor skepticism following previous clinical trial failures.
Competitors of Nektar Therapeutics
ARGX (Argenx) - Growth-Adjusted Payback Ratio|PEG Multiple BNTX (biontech.de)|Growth-Adjusted Market Cap to Net Income Abivax S.A. (ABVX)|ADMA - Price/Earnings to Growth Ratio|Protagonist Therapeutics, Inc. (PTGX) - Price/Earnings to Growth Multiple|Immunovant Therapeutics (IMVT) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple Kiniksa Pharmaceuticals|Price/Earnings to Growth Multiple GRFS|PEG Multiple adaptivebiotech.com|Price/Earnings to Growth Ratio Celldex (CLDX)|Aurinia Pharmaceuticals Inc. - Growth-Adjusted P/E Ratio|PEG Multiple BCRX (biocryst.com)|Vera Therapeutics, Inc. (VERA) - Price to Earnings Adjusted for Growth Rate|Dianthus Therapeutics, Inc. - PEG Multiple|Market Cap to Earnings and Growth Ratio PHVS|ABCL: PEG Multiple|Price to Earnings Adjusted for Growth Rate Tourmaline Corp (TRML)|PGEN (precigen.com) - PEG Multiple|PEG Multiple Pharming Corp|Price/Earnings to Growth Ratio Upstream Bio Inc (UPB)|PEG Multiple zenasbio.com (ZBIO)|Price/Earnings to Growth Ratio Immunome Corp IMNM|PEG Multiple Gossamer Bio Inc GOSS|KALV - Price/Earnings to Growth Ratio|Growth-Adjusted Payback Ratio SEPN (Septerna Pharma)|PVLA (Pieris Pharmaceuticals) - Price/Earnings to Growth Multiple|Savara Inc. - Growth-Adjusted Payback Ratio|RIGL (Rigel Pharmaceuticals, Inc.) - PEG Multiple|Price/Earnings to Growth Ratio ANAB|PEG Multiple ATXS|ENGN - Price to Earnings Adjusted for Growth Rate|PEG Multiple RAPT (rapt.com)|Company Value to Earnings Growth Ratio JBIO (Aerovate)|Aclaris Therapeutics, Inc - PEG Multiple|Price to Earnings Adjusted for Growth Rate Kyverna Therapeutics Inc.|TLSA: PEG Multiple|CABA - Growth-Adjusted Market Cap to Net Income|VTYX (ventyxbio.com) - PEG Multiple|Price to Earnings Adjusted for Growth Rate Theratechnologies Inc. THTX|Price/Earnings to Growth Multiple AVTX (avalotx.com)|Price/Earnings to Growth Multiple Eledon Pharmaceuticals, Inc. ELDN|Price/Earnings to Growth Ratio Agenus, Inc AGEN|Climb Bio Inc - Price/Earnings to Growth Ratio|Zura Bio Limited - PEG Multiple|Growth-Adjusted Market Cap to Net Income aTyr Pharma, Inc. ATYR|ADAG: PEG Multiple|Market Cap to Earnings and Growth Ratio IMA (ImageneBio)|Price/Earnings to Growth Multiple STTK|EQ: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Connect Pharma (CNTB)|PEG Multiple Immunic Therapeutics (IMUX)|PEG Multiple ATRA (Atara Biotherapeutics)|Growth-Adjusted Payback Ratio IFRX|XFOR (X4 Pharma) - Price to Earnings Adjusted for Growth Rate|Growth-Adjusted Payback Ratio ACET (adicetbio.com)|CELU: PEG Multiple|inmunebio.com (INMB) - PEG Multiple|BRNS (Barinthus Biotherapeutics PLC) - PEG Multiple|KZR: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio SAB Biotherapeutics, Inc. (SABS)|AKTX (Akari Therapeutics plc) - Growth-Adjusted Payback Ratio|Price/Earnings to Growth Ratio Enlivex Therapeutics Ltd ENLV|QTTB - Price/Earnings to Growth Multiple|geovax.com - PEG Multiple|Growth-Adjusted Payback Ratio EDSA (Edesa Biotech Inc)|IBIO: PEG Multiple|Carisma Tx (CARM) - PEG Multiple|XTLB (XTL Biopharmaceuticals) - PEG Multiple|BOLT: Growth-Adjusted Payback Ratio|Price/Earnings to Growth Multiple HCWB (HCW Biologics, Inc.)|PEG Multiple Aptevo (APVO)|PEG Multiple AIM (aimimmuno.com)|PEG Multiple Aditxt Corp ADTX|GRI: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio XRTX (xortx.com)|Vyome Holdings Inc. (HIND) - Price/Earnings to Growth Ratio|Revelation Bio (REVB) - PEG Multiple|INDP (Indaptus Corp) - PEG Multiple|SCNI: Growth-Adjusted Payback Ratio|PEG Multiple CALI|Price/Earnings to Growth Multiple Affimed N.V. AFMD|Price/Earnings to Growth Ratio Allakos ALLK|HOOK: Growth-Adjusted P/E Ratio|IGMS - Price/Earnings to Growth Ratio|Growth-Adjusted Market Cap to Net Income iTeos Therapeutics ITOS|Ocean Biomedical (OCEA) - Price/Earnings to Growth Ratio|tcbiopharm.com (TCBP) - PEG Multiple|THRD (Third Harmonic Bio Inc.) - PEG Multiple
